BACKGROUND: The long-term prognosis of endocarditis is described primarily in relation to clinical outcome measures-for example, such complications as cerebrovascular accident, cardiac failure, need for cardiac surgery, relapse rate, and mortality. To our knowledge, to date, no studies have examined the health-related quality of life and the prevalence of long-term persistence of physical symptoms for survivors of left-sided native valve endocarditis. METHODS: We conducted a prospective follow-up study of patients treated for left-sided native valve endocarditis from 1 November 2000 through 31 October 2003 in 23 hospitals in the Netherlands. Of 86 patients eligible to participate, 55 completed questionnaires administered 3 m and 12 m after discharge; an additional 12 patients completed questionnaires 12 m after discharge only, making a total of 67 patients in our study. Persistence of symptoms and employment status were recorded. The health-related quality of life was measured by using the Dutch version of the Medical Outcomes Study Short Form 36-item health survey and the Posttraumatic Stress Disorder questionnaire. RESULTS: Three months after the end of antimicrobial treatment, 41 (75%) of 55 patients still had physical symptoms. Twelve months after the end of antimicrobial treatment, 36 (54%) of 67 patients still had physical symptoms. Before the episode of endocarditis, 30 (81%) of 37 patients aged < or =60 years were employed and working. At 3 m follow-up, 16 (52%) of 31 patients returned to work, and at 12 m follow-up, 24 (65%) of 37 patients were working. One year after discharge, the health-related quality of life was impaired in 5 of 8 dimensions, compared with age-adjusted standard values, and 7 (11%) of 64 patients suffered from posttraumatic stress disorder. CONCLUSIONS: A year after discharge, most survivors of left-sided native valve endocarditis still had persisting symptoms and a seriously diminished quality of life, and 11% of patients suffered from posttraumatic stress disorder.
BACKGROUND: The long-term prognosis of endocarditis is described primarily in relation to clinical outcome measures-for example, such complications as cerebrovascular accident, cardiac failure, need for cardiac surgery, relapse rate, and mortality. To our knowledge, to date, no studies have examined the health-related quality of life and the prevalence of long-term persistence of physical symptoms for survivors of left-sided native valve endocarditis. METHODS: We conducted a prospective follow-up study of patients treated for left-sided native valve endocarditis from 1 November 2000 through 31 October 2003 in 23 hospitals in the Netherlands. Of 86 patients eligible to participate, 55 completed questionnaires administered 3 m and 12 m after discharge; an additional 12 patients completed questionnaires 12 m after discharge only, making a total of 67 patients in our study. Persistence of symptoms and employment status were recorded. The health-related quality of life was measured by using the Dutch version of the Medical Outcomes Study Short Form 36-item health survey and the Posttraumatic Stress Disorder questionnaire. RESULTS: Three months after the end of antimicrobial treatment, 41 (75%) of 55 patients still had physical symptoms. Twelve months after the end of antimicrobial treatment, 36 (54%) of 67 patients still had physical symptoms. Before the episode of endocarditis, 30 (81%) of 37 patients aged < or =60 years were employed and working. At 3 m follow-up, 16 (52%) of 31 patients returned to work, and at 12 m follow-up, 24 (65%) of 37 patients were working. One year after discharge, the health-related quality of life was impaired in 5 of 8 dimensions, compared with age-adjusted standard values, and 7 (11%) of 64 patients suffered from posttraumatic stress disorder. CONCLUSIONS: A year after discharge, most survivors of left-sided native valve endocarditis still had persisting symptoms and a seriously diminished quality of life, and 11% of patients suffered from posttraumatic stress disorder.
Authors: Thomas L Holland; Larry M Baddour; Arnold S Bayer; Bruno Hoen; Jose M Miro; Vance G Fowler Journal: Nat Rev Dis Primers Date: 2016-09-01 Impact factor: 52.329
Authors: Heather A King; Sarah B Doernberg; Julie Miller; Kiran Grover; Megan Oakes; Felicia Ruffin; Sarah Gonzales; Abigail Rader; Michael J Neuss; Hayden B Bosworth; Zoë Sund; Caitlin Drennan; Jonathan M Hill-Rorie; Pratik Shah; Laura Winn; Vance G Fowler; Thomas L Holland Journal: Clin Infect Dis Date: 2021-07-15 Impact factor: 9.079
Authors: Shekhar Saha; Ralitsa Mladenova; Caroline Radner; Konstanze Maria Horke; Joscha Buech; Philipp Schnackenburg; Ahmad Ali; Sven Peterss; Gerd Juchem; Maximilian Luehr; Christian Hagl; Dominik Joskowiak Journal: J Clin Med Date: 2022-06-22 Impact factor: 4.964
Authors: Johan S Bundgaard; Kasper Iversen; Mia Pries-Heje; Nikolaj Ihlemann; Sabine U Gill; Trine Madsen; Hanne Elming; Jonas A Povlsen; Niels E Bruun; Dan E Høfsten; Kurt Fuursted; Jens J Christensen; Martin Schultz; Flemming Rosenvinge; Jannik Helweg-Larsen; Lars Køber; Christian Torp-Pedersen; Emil L Fosbøl; Niels Tønder; Claus Moser; Henning Bundgaard; Ulrik M Mogensen Journal: Qual Life Res Date: 2022-03-29 Impact factor: 3.440
Authors: M Diab; C Sponholz; C von Loeffelholz; P Scheffel; M Bauer; A Kortgen; T Lehmann; G Färber; M W Pletz; T Doenst Journal: Infection Date: 2017-08-30 Impact factor: 3.553
Authors: Leandro Slipczuk; J Nicolas Codolosa; Carlos D Davila; Abel Romero-Corral; Jeong Yun; Gregg S Pressman; Vincent M Figueredo Journal: PLoS One Date: 2013-12-09 Impact factor: 3.240